Evidera
Minh Luu has a diverse work experience spanning multiple industries. They started their career in 2012 as a FY-1 Doctor/Resident Physician at North East Thames Foundation School. In 2013, they moved to Cedars-Sinai Medical Center, where they worked as a Research Associate until 2016. In 2016, Minh Luu joined Xcenda as a Manager in Medical Communications and later became an Assistant Director in Medical Communications in 2020. Their most recent role was at Evidera, where they held the position of Associate Director in Market Access Communications from April 2023.
Minh Luu attended the University of Cambridge from 2006 to 2009, where they obtained a B.A (Hons) degree in Medical Sciences with a focus on Experimental Psychology. Following this, Minh Luu pursued further education at Queen Mary University of London from 2009 to 2012, completing a MD degree in Medicine.
This person is not in any offices
Evidera
1 followers
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.